(Q37862646)

English

Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

author name string

Manfred Kaufmann

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Lajos Pusztai

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Biedenkopf Expert Panel Members

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

0 references

publication date

29 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1575-1582

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene-expression signatures in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Identification of high risk breast-cancer patients by gene expression profiling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Concordance among gene-expression-based predictors for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Standard operating procedure for the collection of fresh frozen tissue samples.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Recommendations for collection and handling of specimens from group breast cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Systematic review: gene expression profiling assays in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Randomized clinical trials with biomarkers: design issues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Standardization of HER2 testing: results of an international proficiency-testing ring study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Proficiency testing of immunohistochemical biomarker assays in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25660

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

release_a256afkcgvecje2ysrqmty36wq

1 reference

https://api.fatcat.wiki/v0/release/a256afkcgvecje2ysrqmty36wq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37862646&oldid=2088597088"